Selected Target Clause Samples

Selected Target. If BMS identifies at least [ * ] mammalian orthologue of such Candidate Target during such [ * ] period, then BMS must provide Exelixis with written notification, prior to the end of such [ * ] period, of its decision to select such Candidate Target as a Selected Target before BMS or its sublicensees may perform any other work on the Candidate Target following the end of such [ * ] period. (ii) If, despite its good faith, Diligent Efforts during the [ * ] period following Exelixis' submission of data regarding a particular Candidate Target to the JSC pursuant to Section 4.5, BMS has been unable to find at least [ * ] mammalian orthologue of such Candidate Target, then BMS shall have an additional [ * ] in which to use good faith, Diligent Efforts to seek to identify at least [ * ] mammalian orthologue of such Candidate Target and, if it so elects, to select such Candidate Target as a Selected Target by providing written notice thereof to Exelixis. (iii) If BMS fails to select such Candidate Target as a Selected Target, within the [ * ] period set forth in subsection (i) above and, if applicable, the additional [ * ] period set forth in subsection (ii) above, then such Candidate Target shall thereafter be deemed an "Abandoned Target," and Exelixis shall have the rights and obligations set forth in Sections 6.3(a) and 6.4. BMS covenants that it shall not perform any further research on such Target or [ * ] mammalian orthologue [ * ] identified by either Party under the Collaboration, and shall not use any such Target or any Research Results relating to such Target [ * ] mammalian orthologue [ * ], except as permitted in clauses (iv) or (v) below. (iv) If, after BMS has abandoned a particular Abandoned Target pursuant to clause (a)(iii) above: (1) BMS or any of its Affiliates learns, [ * ] under the Collaboration, that such Abandoned Target [ * ] mammalian orthologue [ * ] is directly inhibited, agonized or otherwise modulated by a compound in the same class of compounds as the BMS Compound that Exelixis tested in the Mode of Action Program to identify the Candidate Target that became such Abandoned Target; and (2) BMS or such Affiliate [ * ] any material use of any of the Research Results that Remain Confidential at such time [ * ] mammalian orthologues by BMS or its Affiliates that Remain Confidential; then BMS shall thereafter [ * ] such Abandoned Target and/or mammalian orthologues thereof for [ * ] to Exelixis under this Agreement, provided that BMS (or ...
View SourceView Similar (3)
Selected Target. [*] biological or molecular targets identified by UNIVERSITY and accepted by TELIK, against which UNIVERSITY wishes to screen compounds from the TELIK Library pursuant to this Agreement.
View SourceView Similar (2)
Selected Target. Certain confidential information contained in this document, marked by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Certain confidential information contained in this document, marked by [****], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
View Source

Related to Selected Target

  • Research Term The Research Program will be carried out during the two (2) year period following the Effective Date, unless this Agreement is terminated in accordance with Article 13 (such period, as may be extended pursuant to this Section 3.2, being the “Research Term”). BMS shall have the option to extend the Research Term for three (3) additional one (1) year periods on a year-by-year basis after the initial two (2) year period. At least one hundred eighty (180) days prior to the scheduled expiration of the Research Term (i.e., the applicable anniversary of the Effective Date) BMS will provide Ambrx with a nonbinding, good faith indication of whether or not BMS intends to extend the Research Term. In order to exercise its option to extend the Research Term, BMS must provide Ambrx a written notice exercising BMS’ option to extend the Research Term at least ninety (90) days prior to the scheduled expiration of the Research Term (i.e., the applicable anniversary of the Effective Date). If BMS does not provide such written notice, the Research Term will end when scheduled (i.e., on the applicable anniversary of the Effective Date). For each extension of the Research Term, subject to Section 3.4, the JRC will prepare an update to the Research Plan which will include an updated Budget for the BMS-funded Ambrx FTEs to perform the work required under such Research Plan and the projected Third Party Costs.

  • Research Program The term “

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Development Period The Contractor may commence pre-construction activities like utility shifting, boundary wall construction or any other activity assigned to the Contractor by the Authority to enable construction of the Project Highway immediately after signing of the Agreement, to the extent that such work is ready for execution. The Parties agree that these works may be taken up and completed to the extent feasible by the Contractor, before declaration of the Appointed Date, but no claim against the Authority for delay shall survive during this period and that the undertaking of these works by the Contractor shall not count towards the Scheduled Construction Period of the project which starts counting only from the Appointed Date. No construction activity of the Project Highway shall be undertaken during the development period.

  • Desirable Selection Criteria Post registration qualification in the area of specialty or evidence of significant progression towards one.